Dr. Vickie Martin FRCSC
Assistant Professor Division of Oncology & Department of GynecologyAbout
Vickie Martin is a Gynecologic Oncologist at the Saskatchewan Cancer Agency (Saskatoon Site). Vickie Has been active in residency education since completing Fellowship. Upon arriving as a locum she immediately began formal teaching with the residents and once here permanently she became the Gynecologic Oncology representative on the Residency Postgraduate Committee (RPC). She is the Undergraduate representative as well. Vickie received the Residency Doctors of Saskatchewan Excellence in Teaching Award in 2023 and in 2023 was the Provincial Obstetrics & Gynecology recipient of the Dr. David Popkin teaching award. Vickie is now the Saskatoon Site Lead for Gynecology Oncology. She continues to be a member of the Quality Improvement Committee for Gynecologic Oncology
Medical Interests
- Genetics in Gynecological Malignancies
- Low Grade Ovarian cancer
- Fertility Sparing Treatment of Low grade Endometrial Cancers
- Residency Education
Medical Education
- 2008-2010 University of British Columbia, Postgraduate Medical Education Fellowship, Gynecology Oncology,
- 2003-2008 Queen’s University Postgraduate Medical Education, FRCSC Obstetrics and Gynecology
- 1999-2003 Memorial University of Newfoundland, Doctor of Medicine, Dean’s List
- 1994 - 1999 St. Francis Xavier University, Bachelor of Science in Nursing, with Honors (Thesis)
- First Class Honors (Academic)
Clinical Trials
- Principal Investigator (Saskatoon site) NRG-GY019: A Randomized Phase III, Two-arm trial of Paclitaxol/Maintenance Letrozole Versus Letrozole Monotherapy in patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
- Co- investigator for the Senticol Trial -International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer (SENTICOLIII) NCT03386734 (Closed)
- Principal Investigator CCTG ENC1/NRGGY018( Phase III randomized placebo controlled study of Pembrolizumab in addition to paclitaxel and carboplatin for measurable stage III or 4 a, IVB or recurrent endometrial cancer (Closed)